Muscle is an attractive target because it is easily accessible; it also offers a permissive environment for adeno-associated virus (AAV)-mediated gene transfer and has an abundant blood vascular supply providing an efficient transport system for the secretion of proteins. However, gene therapy of dystrophic muscle may be more difficult than that of healthy tissue because of degenerative-regenerative processes, and also because of the inflammatory context. In this study we followed the expression levels of secreted inhibitors of the proinflammatory tumor necrosis factor (TNF) cytokine after intramuscular (i.m.) injection of AAV6 into dystrophic mdx and healthy C57BL/10 mice. We used two chimeric proteins, namely, the human or murine TNF-soluble receptor I fused with the murine heavy immunoglobulin chain. We conducted an AAV6 dose-response study and determined the kinetics of transgene expression. In addition, we followed the antibody response against the transgenes and studied their expression pattern in the muscle. Our results show that transduction efficiency is reduced in dystrophic muscles as compared with healthy ones. Furthermore, we found that the immune response against the secreted protein is stronger in mdx mice. Together, our results underscore that the pathological state of the muscle has to be taken into consideration when designing gene therapy approaches.
Introduction
Duchenne muscular dystrophy (DMD) is an X-linked lethal genetic disease with an incidence of 1 out of 3500 boys. It is caused by mutations in the dystrophin gene, which encodes a large sub-sarcolemmal protein linking the extracellular matrix collagen to the actin cytoskeleton by the sarcolemmal dystrophin-glycoprotein complex. The absence of dystrophin causes the loss of the dystrophin-associated glycoprotein complex at the sarcolemma and results in progressive muscle weakness, cardiomyopathy and early death.
Two decades after the identification of the molecular defect responsible for DMD, there are still no effective cures for the disease. Administration of corticosteroids, such as Prednisone and Deflazacort, are currently the only available pharmacological treatments that have been shown to have a significant beneficial effect by slowing down disease progression. 1 This suggests that inflammation has a significant role in disease progression. Accordingly, DNA microarray experiments conducted on skeletal muscles isolated from 8-week-old dystrophic mdx mice showed that 30% of the 242 identified, differentially expressed genes are related to inflammation. 2 Tumor necrosis factor-a (TNF-a) is one of the proinflammatory cytokines that has a role in muscular dystrophy. Indeed, the plasma levels of TNF-a have been found to be increased in DMD patients. 3 TNF-a has also been shown to induce ubiquitinmediated muscle protein breakdown, 4 which may further contribute to muscle wasting in DMD.
It is interesting that beneficial effects have been observed when Etanercept (a recombinant humansoluble TNF-a receptor that is used for the treatment of rheumatoid arthritis) was injected into mdx mice. 5 This treatment delayed and reduced the breakdown of dystrophic muscles. However, a proteotherapy presents at least two drawbacks. First, the treatment based on recombinant proteins requires regular injections. Second, the blood concentration of therapeutic protein varies strongly with time; there is a high level of soluble receptor shortly after injection, which could lead to side effects, and the level decreases rapidly thereafter, until it drops below the therapeutic level. These pharmacokinetic drawbacks could be overcome by a gene therapy approach.
In this study, we questioned whether the skeletal muscle could be a good target for long-term expression of secreted anti-TNF-a factors. We chose the muscle as it can be very efficiently transduced by different serotypes of adeno-associated virus (AAV) vectors, such as AAV6. 6 Moreover, muscle fibers are able to express and secrete biologically active gene products that are normally not synthesized by this tissue, including coagulation factor IX, 7, 8 a1-antitrypsin, 9 erythropoietin 10 and interleukin-10. 11, 12 In this study we have made use of expression cassettes encoding a chimeric variant of either human-or murine TNF-a-soluble receptor I linked to the Fc (fragment crystallizable) fragment of the mouse immunoglobulin G1 (hTNFR-Is/mIgG1 and mTNFR-Is/mIgG1, respectively). Notably, the human chimeric protein has already proven its efficacy in a rheumatoid arthritis mouse model, 13 as well as in a rat uveitis model. 14 Increasing amounts of pseudotyped 2/6 AAV particles encoding for chimeric proteins were injected into the skeletal muscle of mdx and C57BL/10 mice (the wild-type genetic background of mdx mice, hereafter named B10). By following the expression levels of TNFR-Is levels, we found that injection of the same dose of AAV6 did not lead to the same expression levels in healthy and diseased muscle. This point was confirmed by the administration of an AAV-2/6 vector encoding a murine-secreted alkaline phosphatase (AAV6-muSeAP). We also noticed that a stronger immune response against the transgene occurs in mdx mice as compared with the healthy B10 strain.
Results
Muscle transduction using muSeAP as reporter gene mdx and B10 mice were injected with 2 Â 10 9 vg of AAV6-muSeAP both as a negative control for further TNFR-Is staining experiments and to illustrate the transduction pattern after AAV6 injection of the secreted nonimmunogenic muSeAP transgene. Figure 1a shows an expression of muSeAP in more than 70% of the muscle surface in healthy control B10 mice 35 days after injection. In stark contrast, the expression in dystrophic mdx muscle receiving the same AAV6-muSeAP dose is significantly weaker, with areas of muscle fibers expressing the muSeAP protein scattered over the muscle with no homogeneity.
The plasma levels of muSeAP secreted from the transduced B10 or mdx muscle were also measured to evaluate the kinetics of reporter gene expression. This strategy enables us to indirectly follow the amount of transduced fibers in living mice. As seen in Figure 1b , the muSeAP concentration is significantly higher in B10 (open triangles) compared with mdx mice (filled squares), as early as 7 days after injection. Moreover, it is also interesting that after day 28, the muSeAP concentration in plasma stabilizes in mdx, whereas it continues to grow in the B10 group.
The difference in muSeAP production in mdx mice compared with B10 mice can be explained by the loss of transduced muscle fibers expressing the protein, through cycles of necrosis and regeneration.
Expression patterns of TNFR-Is/mIgG1 transgenes in skeletal muscle Next, we injected B10 and mdx mice with increasing doses of AAV6 encoding for either the human or the murine TNFR-Is/IgG1 chimera.
The hTNFR-Is staining presents an expression pattern that varies with the nature of the injected muscle and the vector dose (Figure 2a) . Indeed, no hTNFR-I expression was seen in control AAV6-muSeAP (data not shown) or in muscles injected with AAV6-hTNFR-Is/mIgG1 in both mouse strains at low vector dose (that is, 2 Â 10 8 vg). With the 5 Â 10 8 vg vector dose, some fibers expressing the protein became apparent in B10 mice, which was, however, not the case in mdx mice. The best expression profile with AAV6-hTNFR-Is/mIgG1 was obtained in B10 animals that received the 2 Â 10 9 vg vector dose. Unexpectedly, injection of a higher dose (that is, 1 Â 10 10 vg) resulted in a weaker expression than that with 2 Â 10 9 vg, with single positive fibers scattered all over the muscle (Figure 2a) .
hTNFR-Is-positive muscle fibers in mdx were only seen in the 2 Â 10 9 vg vector dose group with few weakly stained fibers. The expression of hTNFR-Is in the muscle is thus different from the one obtained with the muSeAP protein at the high vector dose; there are less positive fibers in B10 and mdx in the AAV6-hTNFR-Is/mIgG1-transduced muscle compared with the same condition with AAV6-muSeAP. This discrepancy may be related to an immune response against the hTNFR-Is/mIgG1 transgene.
The expression patterns obtained after AAV6-mTNFRIs/mIgG1 injections are shown in Figure 2b . No endogenous expression of the murine TNFR-I is expected in B10 skeletal muscle. However, we have sometimes noticed mTNFR-I expression in necrotic Transduction of dystrophic muscles using AAV6 G Moulay et al muscle fibers of mdx mice (data not shown), which is in accordance with the expression of its target (the TNF-a) in the mdx context. 15 We have therefore used a primary antibody dilution leading to minimal background, without disturbing the more intense cytoplasmic staining of the transgene in muscle fibers. No staining was seen in B10 or mdx mice injected with control AAV6-muSeAP (data not shown). As for the human chimeric-soluble TNF receptor, no expression of murine TNFR-Is/IgG1 was detected after injection of the 2 Â 10 8 vg vector dose in wild-type B10 or mdx mice (Figure 2b) . Injection of the 5 Â 10 8 vg vector dose in B10 mice produced a homogenous expression, which was detected in more than half of the left tibialis anterior muscle section around the injection point. With the same dose in mdx mice, very few or no fibers were stained. It is interesting that, although the difference between the 2 Â 10 8 and the 5 Â 10 8 vg vector dose is small, the mTNFR-Is/mIgG1 expression in muscle was very different, suggesting that a minimal vector dose is required to overcome the various physiological barriers. After the injection of 2 Â 10 9 vg in B10 mice, almost the entire muscle section was stained for mTNFR-Is/mIgG1, whereas in mdx mice, the mTNFR-Is/mIgG1 expression was significantly weaker. This result is in good agreement with the data obtained using muSeAP as transgene (Figure 1a) . To further test the ability of AAV6-mTNFR-Is/mIgG1 to transduce mdx skeletal muscle, we administered a five times higher dose (1 Â 10 10 vg) in a single injection. A similar mosaic pattern was observed as with the 2 Â 10 9 vg dose, with more fibers expressing the protein and a stronger staining. Together, the differences in expression of the transgene products in dystrophic and wild-type muscles are probably due to the disappearance of transduced fibers with the necrotic process, which takes place in mdx mice. However, we investigated whether the lower expression of the human chimera could also be related to an immune response directed against the transgene.
Kinetics of the expression of TNFRI/mIgG1
We next analyzed the level of secreted transgene products in mdx and control B10 mice through enzymelinked immunosorbent assay (ELISA) quantification of proteins in the plasma.
The hTNFR-Is/mIgG1 was quantified in blood by ELISA using an antibody specific to hTNFR-Is, which was devoid of any crossreactivity to endogenous murinesoluble TNF receptor I. For instance, no hTNFR-Is was detected in the plasma of mice injected with AAV6-muSeAP. The injection of increasing doses of AAV6-hTNFR-Is/mIgG1 in B10 mice resulted in different secretion kinetics (Figure 3a) . At 2 Â 10 8 vg, no hTNFRIs secretion was detected. With the 5 Â 10 8 vg vector dose, the secretion curve rises until day 35, when it reaches an average of 300 pg/ml. At the 2 Â 10 9 vg vector dose, secretion reaches an average of 6000 pg/ml on day 21 and then stabilizes or slightly decreases. To test this decreasing tendency of hTNFR-Is/mIgG1 secretion, we injected five times this latter dose in another group (that is, 1 Â 10 10 vg) and observed a higher but transient secretion with no detectable hTNFR-Is/mIgG1 after day 28.
The injection of AAV6-hTNFR-Is/mIgG1 in mdx also gave a dose-dependent secretion pattern ( Figure 3b ). As in B10 mice, no hTNFR-Is was detected in plasma when injecting 2 Â 10 8 vg. At the 5 Â 10 8 and 2 Â 10 9 vg vector doses, a transient expression was detected, which was significantly lower (30 and 140 times, respectively) than the level obtained with the same vector doses in B10 mice. This weaker transgene secretion in mdx mice is in agreement with the weaker AAV transduction of dystrophic skeletal muscle observed in Figure 2 and Figure 1a . In addition to lower transduction efficiency, an immune response against the transgene could be responsible for the reduced secreted transgenic protein in the plasma. To test the hypothesis of a humoral immune response specific for the transgene, we analyzed the plasma IgG response against hTNFR-Is. 10 vg: AAV6-hTNFR-Is/mIgG1 in B10 mice and AAV6-mTNFR-Is/mIgG1 in mdx. Muscles isolated on day 35 were analyzed by light microscopy after in situ localization of transgene expression using specific antibodies for hTNFR-I and mTNFR-I. Whole TA transverse sections were manually delimited with a black line to enhance the visibility of muscle borders. Scale bars represent 1 mm.
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Indeed, in these mice, no immunoreactive antibodies were detected using a 1/300 plasma dilution (Figure 3d ), and plasma samples were still not immunoreactive using a 1/30 dilution (not shown). One possibility is that a very low antibody response is responsible for this weak transitory expression. Another explanation is that the level of secretion was too low to induce a humoral response, and that the mdx degeneration-regeneration process that takes place in muscle is responsible for the loss of the few transduced fibers. It is also interesting to note that a higher antibody production against hTNFR-Is/mIgG1 was seen in mdx mice as compared with the B10 group. This observation may be explained by the inflammatory context of mdx dystrophic muscle in which more resident macrophages and dendritic cells are present in adult muscles compared with healthy ones. 16 Next, we quantified mTNFR-Is/mIgG1 present in the plasma of injected mice using ELISA. The injection of 2 Â 10 8 vg of AAV6-mTNFR-Is/mIgG1 or of the control AAV6-muSeAP did not produce plasma levels that were above background (Figures 4a and b ). This correlates with the absence of immunostaining in muscle ( Figure 2 ). No expression of mTNFR-I-soluble receptor was detected in mdx mice injected with the 5 Â 10 8 vg vector dose (Figure 4b) . However, the same vector dose injected in wild-type animals resulted in an expression of mTNFR-Is with an average concentration of 125 ng/ml on day 35 after injection ( Figure 4a ). An expression was observed in mdx plasma after the injection of 2 Â 10 9 vg, with a concentration of 250 ng/ml. With the same vector dose, the average plasma concentration reaches a plateau of 1300 ng/ml on day 35 in B10 mice, which is about five times higher than that in mdx mice. The secretion with the 1 Â 10 10 vg dose in mdx starts more rapidly from day 14 compared with the 2 Â 10 9 vg dose, to finally reach approximately the same levels at the end of the experiment.
These results show that, as with other transgenes, we observe a weaker secretion in mdx mice as compared with B10 mice. It is noteworthy that the levels in plasma obtained with the murine-TNFR-I fusion protein were significantly higher than those obtained with human-TNFR-I.
We can also see that there is a good correlation on day 35 between expression in the muscle ( Figure 2 ) and plasma levels (Figures 3 and 4) . This was further confirmed by the results obtained on day 14 with the 2 Â 10 9 vg AAV6-mTNF-R/mIgG1 vector dose in mdx mice. Indeed, at the muscle level, the number of positive fibers was about one-third of that on day 35, whereas the difference in the plasma concentration of the transgene between both time points was 7 (not shown).
In stark contrast to what we found with the hTNFRIs/mIgG1 protein, there were no IgG antibodies produced against the complete murine fusion protein at doses ranging from 2 Â 10 8 to 2 Â 10 9 vg in mdx (Figure 4d ). In B10 mice, only very low (at the limit of detection) and transitory immunoreactive plasma levels were detected in one out of three and two out of three mice with the 5 Â 10 8 and the 2 Â 10 9 vg vector dose, respectively ( Figure 4c ). As murine TNFR-Is/mIgG1 is less immunogenic than hTNFR-Is/mIgG1, the plasma dilution used for the IgG assay was 1/90, whereas it was 1/2490 for the latter. It is interesting that an important immune humoral response was observed in two out of the three mdx mice at the 1 Â 10 10 vg vector dose. But it should be noted that in the two IgG-positive mdx mice, the maximum absorbance is reached on day 21 and thereafter stabilized or decreased, whereas the Transduction of dystrophic muscles using AAV6 G Moulay et al mTNFR-Is/mIgG1 production is still rising, even on day 35 after injection.
These results show that the human chimera is more immunogenic in mouse than the murine one, which is in accordance with previous observations using neoantigens expressed in mouse muscle, such as human coagulation factor IX 7 or ovalbumin. 17 We also show a weaker transduction of dystrophic skeletal muscle, which in turn results in lower levels of secretion of the transgenic protein by the AAV6-transduced muscle. Beyond this difference in transduction efficiency, which is likely due to the cycles of necrosis and regeneration that take place in the dystrophic mdx mouse, the immunogenicity of the transgene product also has an important role as seen with hTNFR-Is/mIgG1. The result obtained in B10 mice with hTNFR-Is when injecting a vector dose of 1 Â 10 10 vg is interesting ( Figure  3a) . The complete loss of secretion suggests the involvement of a cytotoxic response. To analyze this point in more detail, we evaluated the Th1 immune response in mice that were injected with the AAV6-hTNFR-Is/ mIgG1 vector.
T-cell response against hTNFR-Is/mIgG1
We tested the T Helper type 1/T Helper type 2 (Th1/Th2) orientation of the response by measuring the IgG subclasses 2a and 2b against the hTNFR-Is protein in plasma samples collected weekly after muscle injection by AAV6-hTNFR-Is/mIgG1. We also performed immunohistology staining of CD8+ cells in AAV6-hTNFR-Is/ mIgG1-injected muscles.
The The fact that the profile and intensity of the curves between IgG and IgG2b are very similar indicates a humoral immune response against hTNFR-Is/mIgG1, which is mostly Th2 dependent. However, the presence of an IgG2a response against hTNFR-Is with a similar profile to IgG2b suggests a concomitant Th1 immune response.
To go one step further, we performed hematoxylinphloxin-safran staining (HPS; similar to hematoxylineosin except that safran allows for a supplementary staining of collagen) of mdx-and B10-injected muscles, and immunohistochemistry of B10-injected muscles, to characterize the presence of CD8+ cells. HPS staining of mdx muscles revealed the typical alterations observed in dystrophic muscle, including large areas occupied by degenerating and nonmuscle tissues, irregularly shaped fibers mostly centronucleated indicating regeneration, and some ipoeosinophylic necrotic fibers with signs of phagocytosis. In this context, it is difficult to detect histological differences between mdx injected with control nonimmunogenic AAV6-muSeAP and AAV6 encoding the human or murine TNFR-Is chimera. Indeed, no noticeable differences were found (not shown). In contrast, the histological study of healthy B10 tissues was more informative. No centronucleation, inflammatory infiltration or necrosis was observed in mice injected with AAV6-muSeAP or AAV6-mTNFR-Is/mIgG1 at any dose (not shown). The same observations were made in muscles injected with 2 Â 10 8 vg (Figure 6a ) or 5 Â 10 8 vg of AAV6-hTNFR-Is/mIgG1 (not shown). In contrast, monocyte infiltration was visible at the 2 Â 10 9 vg dose (Figure 6b ). This was also the case with the 1 Â 10 10 vg 
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In situ detection of transgene (red) and CD8 expression (green) was carried out on TA isolated on day 35 and analyzed by fluorescence microscopy. Sections were nuclear counterstained with DAPI. Panels (d) to (f) represent B10 muscles injected, respectively, with 2 Â 10 8 , 2 Â 10 9 and 1 Â 10 10 vg of AAV6-hTNFR-Is/mIgG1. Panels (g) and (h) represent mdx muscles injected, respectively, with 2 Â 10 8 and 2 Â 10 9 vg of AAV6-hTNFR-Is/mIgG1. Scale bars represent 100 mm.
Transduction of dystrophic muscles using AAV6 G Moulay et al dose in which we also noticed extensive centronucleation (which signals active muscle fiber regeneration) (Figure 6c ). Thus, hTNFR-Is/mIgG1 triggered a dosedependent inflammatory response. No CD8+ cells were present in mdx or B10 mice after injection of the low 2 Â 10 8 vg vector dose of AAV6-hTNFR-Is/mIgG1 (B10 mice presented in Figure 6d ). Similarly, no CD8+ cells were found in mdx or B10 mice injected with the 2 Â 10 9 vg vector dose of AAV6-mTNFR-Is/mIgG1 or AAV6-muSeAP (data not shown).
In panels E, F and H of Figure 6 , one can see that hTNFRIs-positive cells (red stained) are surrounded by CD8+ cells (in green). The number of CD8+ cells increases with the vector dose in B10 mice (compare 2 Â 10 9 vg shown in Figure 6e with 1 Â 10 10 vg illustrated in Figure 6f ). In the mdx muscle, few transduced cells are present and a higher CD8+ cell number is visible as compared with the same vector dose in B10 (compare panels G/H with D/E). Figure 6f illustrates the destruction of hTNFR-Is/ mIgG1-transduced muscle fibers through a cellular cytotoxic immune response (correlated with a CD8+ cell infiltration), which explains the poorer expression pattern seen with 1 Â 10 10 vg as compared with 2 Â 10 9 ( Figure 2 ). Although an equivalent basal amount of CD8+ cells in mdx muscle compared with healthy muscle has been reported, 16 we observe a greater CD8 infiltration against the immunogenic hTNFR-Is/mIgG1 transgene in mdx mice.
Discussion
Skeletal muscle is an important target for gene therapy because many genetic disorders affect this tissue. In addition, as muscle is efficiently transduced by AAV vectors, i.m. administration represents an attractive system for the secretion and production of therapeutic factors, such as factor IX. On the other hand, a possible limitation of this latter approach is that the secretion of proteins after AAV-mediated muscle gene transfer can be limited by an immune response. 17 The aim of this study was to evaluate whether a dystrophic mouse muscle can be used for long-term expression of a therapeutic factor. In muscular dystrophies, inflammation has a significant role in the progression of the disease. This may explain the beneficial (but still limited) effect for DMD patients of prednisone/ deflazacort treatments. An alternative to regular administration of high doses of corticosteroids would be the use of gene therapy for sustained expression of antiinflammatory agents. In this case, one interesting target could be chemokine ligand 2 (or monocyte chemoattractant protein-1), which has been found to be one of the most upregulated genes involved in inflammation in dystrophic mice. 18 Gene therapy-mediated production of the specific inhibitor of monocyte chemoattractant protein-1 called 7ND 19 could thus represent an interesting strategy. Another approach could consist of using RNA interference to reduce the levels of various proinflammatory factors. 20 In this work, we focused on the proinflammatory cytokine TNF-a. The rationale for this choice is based on the fact that (1) TNF-a is overexpressed in DMD patients 21 and (2) a proteotherapy consisting of regular injections of Etanercept, a recombinant human-soluble TNF-a receptor, delayed and reduced the breakdown of dystrophic muscles in mdx mice. 22 To evaluate the influence of the dystrophic context on transgene expression, we have conducted the same study in parallel in healthy B10 mice that have the same genetic background as mdx. The first experiments aimed to compare the transduction efficiency by AAV6 of healthy and dystrophic muscles. We took advantage of the reporter gene muSeAP, which leads to a nonimmunogenic protein allowing specific detection in blood and tissues with a low background because of higher thermostability compared with endogenous phosphatases. The results showed that muSeAP was expressed and secreted in blood throughout the experiment, but phosphatase staining on muscle slices and level of secretion were weaker in mdx compared with B10 mice (Figure 1) . The weaker expression and secretion can be attributed to the loss of transduced muscle fibers due to the cycles of necrosis and regeneration. This is in agreement with results published by Abmayr et al., which show that both Igf-1 mRNA and vector genome levels after i.m. injection of rAAV6-mIGF-1 in mdx mice declined, unless a second rAAV6 encoding a microdystrophin that enables a stabilization of myofiber turnover was codelivered. 23 After this control experiment, we performed assays using a recombinant AAV6 vector encoding the human TNF-a-soluble receptor I linked to the Fc (fragment crystallizable) fragment of the mouse immunoglobulin G1, which has previously shown its efficacy in both a rheumatoid arthritis mouse model 13 and a rat uveitis model. 14 In agreement with muSeAP experiments, results showed a reduced muscle transduction efficiency and secretion of hTNFR-Is/mIgG1 in mdx as compared with B10 mice. Another difference between mdx and B10 was the transient nature of the expression in mdx. As already mentioned above, this effect is probably due to the degeneration-regeneration process, which takes place in the dystrophic muscle that progressively leads to the loss of some transduced fibers. However, two observations pointed toward the generation of an immune response against hTNFR-Is/mIgG1: first, the fact that in B10 mice a lower number of fibers expressed the transgene as compared with muSeAP; second, injection of 1 Â 10 10 vg resulted in weaker expression than did injection with 2 Â 10 9 vg. The analysis of the plasma IgG response against hTNFR-Is/mIgG1 confirmed the generation of an antibody response against the transgene. Measurements of IgG subclasses 2a and 2b against the hTNFR-Is protein in plasma samples and detection of CD8+ cells in AAV6-hTNFR-Is/mIgG1-injected muscles further showed that the hTNFR-Is/ mIgG1 transgene also stimulated a cellular immune response against transduced healthy and dystrophindeficient muscle fibers. It is noteworthy that the CD8+ cell response in B10 mice is strongest in the group treated with 1 Â 10 10 vg as shown by the following observations: (1) the transient secretion of hTNFR-Is/mIgG1, (2) the presence of a high number of CD8+ cells in muscle tissue and (3) high level of centronucleation on day 35, which is characteristic of active muscle fiber regeneration.
It is interesting that the humoral Th2, as well as cellular Th1 responses, were exacerbated in mdx mice, as compared with B10. This enhanced reaction in mdx mice, even though the basal CD8 amount is initially Transduction of dystrophic muscles using AAV6 G Moulay et al comparable in mdx and B10, may be due to the presence of a greater number of dendritic cells in dystrophic muscles. 16 We also checked for the humoral response against AAV6 capsid proteins. This study has been conducted by an ELISA using plasma of AAV6-muSeAP-and AAV6-mTNFR-Is/mIgG1-injected mice. Anti-AAV6 IgG levels in B10 and mdx mice were comparable at every time point and vector dose tested (data not shown). The absence of difference in antibody response between the two mouse strains may be explained by the fact that the amount of injected AAV6 particles (that is, antigen) in all groups is too elevated to allow a discrimination in the response. It is of note that the same observation, that is, absence of difference in antibody response, between mdx and B10 has been reported after i.m. injection of AAV2 vectors. 24 Moreover, it has to be mentioned in this study that the immune response to AAV largely depends on the animal models. Indeed, unlike studies in mice, i.m. injection of AAV6 in wild-type and dystrophic dogs has been shown to elicit a robust T-cell-mediated immune response. 25 However, more important, the latter can be mastered by a short course of immunosuppression. 26 Owing to the immune response against the human chimera, we decided to conduct the same study using a fully murine chimeric protein (mTNFR-Is/mIgG1). As with muSeAP and hTNFR-Is/mIgG1 transgenes, we found a weaker expression in mdx as compared with B10 mice. However, in contrast to hTNFR-I, there was no specific antibody response against mTNFR-I after injection of doses ranging from 2 Â 10 8 to 2 Â 10 9 vg in mdx. In B10 mice, only a very low and transitory humoral response was found. Even though species specific, it is known that these kinds of chimeric proteins can produce a humoral response because of antigenic epitopes formed at the junction between the two original proteins. It is interesting that a strong immune humoral response specific to mTNFRI was observed in two out of the three mdx mice at the 1 Â 10 10 vg vector dose. However, this response did not lead to a suppression of transgene expression.
In conclusion, using three different secreted transgenes and AAV6 as a vector, we have found that expression levels are lower after i.m. injection into dystrophic as compared with healthy muscles. We also showed that when using non-(muSeAP) or poorly immunogenic (mTNFR-Is/mIgG1) transgenes, the expression is possible for a longer period of time in dystrophic muscles. Further, in agreement with a previous study, 27 we show that the immune response in healthy mice against an immunogenic transgene such as hTNFR-Is/mIgG1 is dose dependent. Although injection of 5 Â 10 8 and 2 Â 10 9 vg may allow for long-term expression, administration of 1 Â 10 10 resulted in only a transient expression. Finally, our results show that a long-term study of the therapeutic potential of mTNFRIs/mIgG1 in mdx mice may not be possible without readministration. Alternatively, such an approach has to be associated with a second treatment, which avoids muscle degeneration. This latter result may be obtained using different strategies, including a gene therapy approach allowing for dystrophin, mini-or microdystrophin expression;
23 gene transfer-mediated overexpression of utrophin; 28 antisense approaches consisting of the delivery of oligonucleotides (or rAAVs allowing their production) targeted to splicing elements of the dystrophin pre-mRNA that can induce exon skipping and thereby restore the open reading frame and the production of a functional dystrophin; 29 ribosomal readthrough of premature termination codons by compounds such as PTC124; 30 or pharmacological treatment to increase levels of utrophin. 31 
Materials and methods

Expression cassettes
The pXL3937-CMV-muSeAP plasmid obtained from Vincent Thuiller 32 contains muSeAP cDNA subcloned into an AAV plasmid backbone, which has the ITRs of AAV2. The cDNA of the soluble murine TNFR1 was cloned as follows: Total RNA was extracted from a C57Bl6 mouse brain using TriZol reagent (Gibco BRL, Cergy Pontoise, France). A reverse transcription reaction was then performed with the Superscript II enzyme (Invitrogen, Cergy Pontoise, France) using the primer 5 0 -TTAGGCAGTACCTGAGTCCTGGG-3 0 (on the basis of X57796 Genbank sequence of murine TNFR1 receptor). The product was amplified by a standard PCR reaction (Accuzyme enzyme, Abcys, Paris, France) using the following primers: 5 0 -CGCTCCGGAGCCACCATGGGT CTCCCCACCGTGCCTG-3 0 for the upper primer and 5 0 -TCAGGATCCACGCGGAACCAGGGCAGTACCTGA GTCCTGGGGGTT-3 0 for the lower primer. To construct the mTNFR-Is/mIgG1 fusion sequence, the PCR product (mTNFR-Is) was digested with BspE1 and BamH1 and ligated into a pVAX2 encoding hTNFR-Is/ mIgG1 in place of hTNFR-Is. The resulting plasmid was checked by DNA sequencing. pGG2-CMV-hTNFR-Is/ mIgG1 and pGG2-CMV-mTNFR-Is/mIgG1 expression cassettes were generated by cloning the hTNFR-Is/ mIgG1 13 and mTNFR-Is/mIgG1 sequences into the pGG2 AAV vector plasmid. The three resulting AAV vector plasmids are under the transcriptional control of the cytomegalovirus immediate-early promoter and SV40 polyA sequence. These plasmids encode, respectively, a secreted form of the murine alkaline phosphatase, 32 and for the human and murine TNF-a-soluble receptor I fused with the murine heavy immunoglobulin chain. It is noteworthy that we have verified that the mTNFR-Is/mIgG1 plasmid produced a functional protein (data not shown).
Recombinant AAV6 vector production
Pseudotyped AAV vectors were generated by packaging AAV2-based recombinant genomes in AAV6 capsids. AAV6 vectors were produced in an adenovirus-free system by triple transfection using polyethylenimine (PEI 25 kDa; Sigma-Aldrich) as described previously. 33 Briefly, human embryonic kidney 293 cells were transfected in 15-cm plates with the trans-complementing adenovirus helper plasmid pXX6; 34 the pLT-RC06 packaging plasmid expressing the AAV2 rep gene and the AAV6 cap gene; and a cis-acting AAV vector plasmid (pXL3937-CMV-muSeAP, pGG2-CMV-hTNFR-Is/mIgG1 or pGG2-CMV-mTNFR-Is/mIgG1). After 72 h of transfection, the cells underwent four cycles of freeze/thaw; the crude lysate was then treated with 25 U/ml benzonase, and AAV vectors were precipitated with cold saturated ammonium sulfate before purification by double CsCl 2 ultracentrifugation gradient. This step was for AAV6-mTNFR-Is/mIgG1 and 4.3 Â 10 11 vg/ml for AAV6-muSeAP.
In vivo experiments
Female C57BL/10 (B10) and mdx mice (Charles River, France) (8-10 weeks of age) were anesthetized by intraperitoneal injection of 100 mg of ketamine and 10 mg of xylazine per kilogram of body weight, and then injected with AAV6 preparations in a final volume of 25 ml in the left tibialis anterior muscle TA. A doseresponse study was carried out with AAV6-hTNFR-Is/ mIgG1 and AAV6-mTNFR-Is/mIgG1, with three groups of B10 and mdx mice receiving either 2 Â 10 8 , 5 Â 10 8 or 2 Â 10 9 vg of each vector (3-5 mice per group). Two additional groups were injected with 1 Â 10 10 vg: AAV6-hTNFR-Is/mIgG1 in B10 and AAV6-mTNFR-Is/mIgG1 in mdx (three mice per group). The AAV6-muSeAP vector was injected at 2 Â 10 9 vg per TA. Retro-orbital plexus blood samples were obtained from anesthetized mice before injection and thereafter every week using heparinized capillary tubes. Plasma samples were obtained by centrifugation at 4000 g for 15 min and either analyzed immediately or stored at À20 1C. Mice were killed by cervical dislocation 35 days after injection. The AAV-injected TA muscles were collected and frozen in liquid nitrogen-cooled isopentane. Muscles were conserved at À80 1C until histological analysis. All animal procedures and care were performed in accordance with regulatory guidelines.
Histological analysis
In situ muSeAP and HPS histochemical staining procedures were performed on 8 mm TA transversal cryosections. The muSeAP detection on muscle sections was performed on slices fixed with 0.5% glutaraldehyde. Slices were washed twice with PBS and endogenous alkaline phosphatase was heat inactivated for 30 min at 65 1C before a 5 h incubation at 37 1C in 0.165 mg/ml 5-bromo-4-chloro-3-indolylphosphate and 0.33 mg/ml of nitroblue tetrazolium (Promega) in 100 mM Tris-HCl, 100 mM NaCl and 50 mM MgCl 2 . Sections were then counterstained with nuclear fast red, mounted and analyzed by light microscopy. Inflammation and muscle integrity were evaluated following HPS staining. Nonoverlapping tiled images of complete transverse muscle sections were obtained using Cartograph software (Microvision, France) and a Nikon Eclipse E600 microscope with a Sony 3CCD DSP camera system using a Â 4 magnification objective. HPS photographs were taken using a Â 10 magnification objective.
Immunohistochemistry
Immunostaining of mTNFR-Is, hTNFR-Is and murine CD8 was performed on 8 mm TA transversal cryosections. For mTNFR-Is or hTNFR-Is staining, slices were dried and endogenous peroxidases were inactivated by incubation with diluted H 2 O 2 . Polyclonal goat antibody against human or murine TNFR-Is (R&D Systems) at 1.5 mg/ml was used as the primary antibody. Primary antibodies were detected using 2.5 mg/ml of HRPconjugated polyclonal rabbit anti-goat IgG antibody (DAKO). The immune complex labeled with horseradish peroxidase (HRP) was visualized with diaminobenzidine (DAB; DAKO). Double immunostaining of CD8+ cells and human or murine TNFR-I was performed using the primary antibodies described above and with a rat monoclonal antibody against mouse CD8-a at 5 mg ml
À1
(clone CT-CD8a; Caltag Laboratories). The following secondary antibodies were used: AlexaFluor 594-conjugated polyclonal donkey anti-goat IgG at 2 mg ml À1 (Invitrogen molecular probes) and biotinylated polyclonal rabbit anti-rat IgG at 3.85 mg ml À1 (DAKO) with AlexaFluor 488-conjugated streptavidin used at 5 mg ml À1 (Invitrogen molecular probes). A 1/50 mouse serum dilution (DAKO) was used in conjunction with the biotinylated rabbit anti-rat IgG antibody to avoid crossreactivity with murine IgG present in dystrophic muscle tissue. Finally, DAPI was added to stain the nuclei. Photographs of DAB-stained transverse TA sections were obtained as described for muSeAP histological analysis. Immunofluorescent images were taken by using a Zeiss Axiophot2 microscope coupled to a Hamamatsu color-chilled 3CCD camera and a 20X magnification objective.
Blood analysis
The amount of muSeAP present in plasma was quantified by chemiluminescent detection of enzyme activity. Briefly, endogenous alkaline phosphatase was heat inactivated for 5 min at 65 1C and the heat-resistant muSeAP was quantified by addition of the reaction buffer and CSPD chemiluminescent substrate, according to the manufacturer's instructions (Phosphalight kit Tropix, Applera). Chemiluminescence was measured in a 96-well plate format with a luminometer (Perkin Elmer, Victor 2 1420 Multilabel counter). Expression levels were determined using a standard curve of purified human placental alkaline phosphatase and expressed as per gram of muSeAP per ml of plasma.
The levels of hTNFR-Is/mIgG1 and mTNFR-Is/ mIgG1 were quantified by an ELISA according to the manufacturer's protocol. The mTNFR-Is ELISA (R&D Systems, France) recognizes both endogenous soluble TNF receptor I and the transgenic protein mTNFR-Is/mIgG1 in mouse plasma. The hTNFR-Is ELISA (R&D Systems, France) recognizes only the hTNFR-Is/mIgG1 protein with no crossreactivity to the endogenous murine-soluble TNF receptor I. TNFR-Is ELISA quantifications are made against standard curves of the corresponding recombinant TNFR-I proteins; therefore, results presented are expressed as monomeric equivalent mass per ml of recombinant proteins.
Humoral immune response against the transgenes
The IgG antibody levels against our transgenic proteins were measured by ELISA. Human or murine recombinant TNFR-I (R&D Systems, France) was coated overnight at room temperature on clear polystyrene microplates at 200 ng ml À1 in 100 ml of PBS. Plates were then washed with PBS-T (PBS 0.05% Tween20) and blocked for 2 h with PBS 1% BSA. Plasma samples were incubated in the plate wells for 2 h. ELISA plates showed a 1/5000 dilution of an HRP-conjugated polyclonal sheep anti-mouse IgG antibody (RPN4201 Amersham), Transduction of dystrophic muscles using AAV6 G Moulay et al incubated for 2 h at room temperature, followed by a TMB and H 2 O 2 substrate (BD Biosciences) revelation. The chromogenic reaction was stopped with 1 M sulfuric acid and the absorbance read at 450 nm. Plasma was considered immunoreactive when absorbance measured after injection was twice that of the naive plasma collected before AAV injection. The same ELISA protocol as for the IgG assay was used to measure subclasses IgG2a and IgG2b against hTNFR-Is with the following detection antibodies: HRPconjugated polyclonal goat anti-mouse IgG2a or IgG2b at 1/4000 dilution (SouthernBiotech). Plasma dilutions used were 1/30 for IgG2a assay and 1/300 for IgG2b assay.
Statistical analysis
All data are expressed as means±s.d. Differences between two groups were tested using the nonparametric Mann-Whitney test. Statistical significance was defined by a two-tailed P-value below 0.05.
